Filing Details
- Accession Number:
- 0001209191-23-001186
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-04 17:26:29
- Reporting Period:
- 2022-12-30
- Accepted Time:
- 2023-01-04 17:26:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1253689 | Glycomimetics Inc | GLYC | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1237289 | D Scott Sandell | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-12-30 | 66,690 | $3.02 | 4,928,974 | No | 4 | S | Indirect | See Note 2 |
Common Stock | Disposition | 2022-12-30 | 54,645 | $3.02 | 4,038,732 | No | 4 | S | Indirect | See Note 3 |
Common Stock | Disposition | 2023-01-03 | 96,084 | $2.99 | 4,832,890 | No | 4 | S | Indirect | See Note 2 |
Common Stock | Disposition | 2023-01-03 | 78,730 | $2.99 | 3,960,002 | No | 4 | S | Indirect | See Note 3 |
Common Stock | Disposition | 2023-01-04 | 56,054 | $2.91 | 4,776,836 | No | 4 | S | Indirect | See Note 2 |
Common Stock | Disposition | 2023-01-04 | 45,930 | $2.91 | 3,914,072 | No | 4 | S | Indirect | See Note 3 |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Note 2 |
No | 4 | S | Indirect | See Note 3 |
No | 4 | S | Indirect | See Note 2 |
No | 4 | S | Indirect | See Note 3 |
No | 4 | S | Indirect | See Note 2 |
No | 4 | S | Indirect | See Note 3 |
Footnotes
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.93 to $3.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The Reporting Person is a general partner of NEA Partners 10, Limited Partnership ("NEA Partners 10"). NEA Partners 10 is the sole general partner of New Enterprise Associates 10, Limited Partnership ("NEA 10"), the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which the Reporting Person has no pecuniary interest.
- The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securitites Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.86 to $3.225 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.